Concepts (340)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hearing Loss | 68 | 2025 | 212 | 14.730 |
Why?
|
| Hearing Aids | 13 | 2025 | 32 | 4.040 |
Why?
|
| Cognitive Dysfunction | 15 | 2025 | 315 | 2.730 |
Why?
|
| Cochlear Implants | 4 | 2017 | 59 | 1.500 |
Why?
|
| Aged | 71 | 2025 | 21471 | 1.380 |
Why?
|
| Geriatrics | 3 | 2021 | 70 | 1.260 |
Why?
|
| Ependymoma | 3 | 2025 | 177 | 1.230 |
Why?
|
| Atherosclerosis | 9 | 2025 | 1006 | 1.190 |
Why?
|
| Aging | 16 | 2025 | 1251 | 0.960 |
Why?
|
| Loneliness | 3 | 2025 | 35 | 0.940 |
Why?
|
| Exercise | 5 | 2025 | 860 | 0.920 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2024 | 215 | 0.910 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 701 | 0.910 |
Why?
|
| Aged, 80 and over | 35 | 2025 | 7128 | 0.880 |
Why?
|
| Brain Neoplasms | 6 | 2023 | 1404 | 0.870 |
Why?
|
| Male | 77 | 2025 | 65006 | 0.850 |
Why?
|
| Community Health Workers | 2 | 2022 | 77 | 0.850 |
Why?
|
| Gangliosides | 1 | 2024 | 73 | 0.820 |
Why?
|
| Mobility Limitation | 2 | 2021 | 33 | 0.820 |
Why?
|
| Cognition | 9 | 2025 | 811 | 0.790 |
Why?
|
| Female | 77 | 2025 | 70778 | 0.790 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 429 | 0.780 |
Why?
|
| Retinoblastoma | 2 | 2021 | 112 | 0.780 |
Why?
|
| Retinal Neoplasms | 2 | 2021 | 101 | 0.770 |
Why?
|
| Quality of Life | 6 | 2024 | 2165 | 0.760 |
Why?
|
| Accidental Falls | 3 | 2025 | 115 | 0.760 |
Why?
|
| Depression | 6 | 2024 | 1352 | 0.750 |
Why?
|
| Humans | 103 | 2025 | 132236 | 0.730 |
Why?
|
| Dementia | 6 | 2022 | 470 | 0.700 |
Why?
|
| Health Services for the Aged | 1 | 2021 | 40 | 0.680 |
Why?
|
| Pyrimidines | 2 | 2021 | 418 | 0.680 |
Why?
|
| Health Education | 5 | 2025 | 235 | 0.680 |
Why?
|
| Geriatric Assessment | 5 | 2024 | 192 | 0.660 |
Why?
|
| Hearing | 7 | 2023 | 61 | 0.600 |
Why?
|
| Deaf-Blind Disorders | 1 | 2018 | 1 | 0.590 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2018 | 3 | 0.590 |
Why?
|
| Pyrazoles | 1 | 2021 | 330 | 0.590 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 484 | 0.580 |
Why?
|
| Neurosurgical Procedures | 2 | 2024 | 317 | 0.570 |
Why?
|
| Communication | 3 | 2024 | 542 | 0.570 |
Why?
|
| Speech Perception | 3 | 2024 | 57 | 0.540 |
Why?
|
| Congresses as Topic | 1 | 2018 | 186 | 0.530 |
Why?
|
| Body Composition | 1 | 2020 | 550 | 0.520 |
Why?
|
| Independent Living | 5 | 2024 | 73 | 0.520 |
Why?
|
| Mental Health Services | 1 | 2020 | 281 | 0.520 |
Why?
|
| Cross-Sectional Studies | 16 | 2024 | 3763 | 0.510 |
Why?
|
| Prospective Studies | 16 | 2025 | 6572 | 0.500 |
Why?
|
| Audiometry, Pure-Tone | 9 | 2025 | 25 | 0.500 |
Why?
|
| Cost of Illness | 1 | 2017 | 285 | 0.470 |
Why?
|
| Health Care Costs | 1 | 2019 | 415 | 0.460 |
Why?
|
| Stress, Psychological | 1 | 2020 | 577 | 0.460 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 167 | 0.460 |
Why?
|
| Germ-Line Mutation | 4 | 2025 | 368 | 0.450 |
Why?
|
| Accelerometry | 3 | 2025 | 64 | 0.450 |
Why?
|
| Middle Aged | 23 | 2025 | 29032 | 0.450 |
Why?
|
| Computers | 1 | 2014 | 69 | 0.440 |
Why?
|
| Vision Disorders | 5 | 2023 | 217 | 0.440 |
Why?
|
| Ear Diseases | 1 | 2014 | 22 | 0.440 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 396 | 0.430 |
Why?
|
| Societies, Medical | 1 | 2018 | 779 | 0.430 |
Why?
|
| Health Status Indicators | 1 | 2014 | 128 | 0.420 |
Why?
|
| Social Environment | 1 | 2014 | 122 | 0.420 |
Why?
|
| Age Factors | 8 | 2022 | 2920 | 0.410 |
Why?
|
| Ribonuclease III | 2 | 2025 | 99 | 0.400 |
Why?
|
| United States | 20 | 2025 | 11688 | 0.390 |
Why?
|
| Prevalence | 9 | 2023 | 2665 | 0.390 |
Why?
|
| Language | 1 | 2014 | 225 | 0.390 |
Why?
|
| Noise | 2 | 2024 | 21 | 0.370 |
Why?
|
| Glioma | 3 | 2024 | 533 | 0.370 |
Why?
|
| Presbycusis | 3 | 2024 | 4 | 0.360 |
Why?
|
| Child | 20 | 2025 | 25783 | 0.330 |
Why?
|
| Leisure Activities | 3 | 2025 | 10 | 0.330 |
Why?
|
| Risk Factors | 17 | 2025 | 10948 | 0.330 |
Why?
|
| Carotid Artery Diseases | 2 | 2023 | 137 | 0.320 |
Why?
|
| Walking | 3 | 2025 | 234 | 0.300 |
Why?
|
| Social Isolation | 2 | 2025 | 48 | 0.280 |
Why?
|
| Disability Evaluation | 3 | 2020 | 198 | 0.280 |
Why?
|
| Child, Preschool | 12 | 2025 | 14735 | 0.260 |
Why?
|
| Medicare | 4 | 2023 | 447 | 0.240 |
Why?
|
| Baltimore | 3 | 2024 | 18 | 0.240 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 302 | 0.230 |
Why?
|
| Longitudinal Studies | 7 | 2024 | 1500 | 0.230 |
Why?
|
| Pinealoma | 1 | 2025 | 22 | 0.230 |
Why?
|
| Pineal Gland | 1 | 2025 | 21 | 0.230 |
Why?
|
| Odontoid Process | 1 | 2024 | 10 | 0.230 |
Why?
|
| Chordoma | 1 | 2024 | 20 | 0.220 |
Why?
|
| Television | 1 | 2025 | 71 | 0.220 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2025 | 147 | 0.220 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2025 | 74 | 0.220 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.220 |
Why?
|
| Pilot Projects | 3 | 2019 | 1445 | 0.220 |
Why?
|
| Feasibility Studies | 3 | 2023 | 821 | 0.220 |
Why?
|
| Astrocytoma | 1 | 2025 | 111 | 0.220 |
Why?
|
| Anxiety | 3 | 2022 | 1002 | 0.220 |
Why?
|
| Nutrition Surveys | 3 | 2021 | 314 | 0.210 |
Why?
|
| Brain | 6 | 2024 | 3183 | 0.210 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2023 | 153 | 0.210 |
Why?
|
| Cervical Vertebrae | 1 | 2024 | 117 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 5412 | 0.210 |
Why?
|
| Olfaction Disorders | 1 | 2024 | 30 | 0.210 |
Why?
|
| Wilms Tumor | 1 | 2025 | 119 | 0.210 |
Why?
|
| Fatigue | 1 | 2024 | 201 | 0.200 |
Why?
|
| Proton Therapy | 1 | 2025 | 159 | 0.200 |
Why?
|
| Infant | 8 | 2025 | 13048 | 0.200 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2023 | 43 | 0.200 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2022 | 24 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 39 | 0.200 |
Why?
|
| Precision Medicine | 2 | 2024 | 360 | 0.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2022 | 74 | 0.190 |
Why?
|
| Medical Oncology | 1 | 2024 | 244 | 0.190 |
Why?
|
| Deafness | 1 | 2023 | 85 | 0.190 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 83 | 0.190 |
Why?
|
| Patient Outcome Assessment | 1 | 2022 | 94 | 0.190 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 18 | 0.180 |
Why?
|
| Hypertension | 2 | 2022 | 1398 | 0.180 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 65 | 0.180 |
Why?
|
| Receptor, trkB | 1 | 2021 | 25 | 0.180 |
Why?
|
| Sensation Disorders | 1 | 2021 | 24 | 0.180 |
Why?
|
| Odds Ratio | 3 | 2020 | 1257 | 0.180 |
Why?
|
| White Matter | 2 | 2020 | 211 | 0.180 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2025 | 302 | 0.180 |
Why?
|
| Frailty | 1 | 2023 | 136 | 0.170 |
Why?
|
| Waiting Lists | 1 | 2022 | 237 | 0.170 |
Why?
|
| Neuropsychological Tests | 2 | 2023 | 990 | 0.170 |
Why?
|
| Cigarette Smoking | 1 | 2022 | 80 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2023 | 5173 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 450 | 0.170 |
Why?
|
| Propensity Score | 2 | 2019 | 256 | 0.170 |
Why?
|
| Gadolinium | 1 | 2021 | 116 | 0.170 |
Why?
|
| Ganglioglioma | 1 | 2020 | 22 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3844 | 0.160 |
Why?
|
| Neoplasms | 3 | 2024 | 2961 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2025 | 3356 | 0.160 |
Why?
|
| Corpus Callosum | 1 | 2020 | 104 | 0.160 |
Why?
|
| Self Report | 5 | 2025 | 554 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2021 | 198 | 0.160 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2020 | 16 | 0.160 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2020 | 20 | 0.160 |
Why?
|
| Supratentorial Neoplasms | 1 | 2020 | 40 | 0.160 |
Why?
|
| Mental Health | 3 | 2023 | 377 | 0.160 |
Why?
|
| Frail Elderly | 2 | 2023 | 107 | 0.160 |
Why?
|
| Adolescent | 9 | 2025 | 20559 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 20 | 0.160 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 29 | 0.160 |
Why?
|
| Interdisciplinary Research | 1 | 2019 | 10 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 153 | 0.160 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2019 | 27 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 1829 | 0.150 |
Why?
|
| Genetic Counseling | 1 | 2021 | 246 | 0.150 |
Why?
|
| Sex Factors | 3 | 2021 | 1354 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 420 | 0.150 |
Why?
|
| Radiation Dosage | 1 | 2019 | 146 | 0.150 |
Why?
|
| Communication Barriers | 1 | 2018 | 42 | 0.140 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 857 | 0.140 |
Why?
|
| Patient Participation | 1 | 2021 | 240 | 0.140 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 824 | 0.140 |
Why?
|
| Hearing Loss, Unilateral | 1 | 2017 | 8 | 0.140 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 158 | 0.140 |
Why?
|
| Minority Health | 1 | 2017 | 13 | 0.140 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 37 | 0.140 |
Why?
|
| Azepines | 1 | 2018 | 64 | 0.140 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2017 | 18 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 462 | 0.140 |
Why?
|
| Oximes | 1 | 2017 | 56 | 0.130 |
Why?
|
| Panniculitis | 1 | 2017 | 19 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 899 | 0.130 |
Why?
|
| Biomarkers, Tumor | 4 | 2023 | 1679 | 0.130 |
Why?
|
| Neuroimaging | 1 | 2020 | 374 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 211 | 0.130 |
Why?
|
| Automobile Driving | 1 | 2017 | 34 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 630 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2019 | 1234 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 124 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2017 | 132 | 0.130 |
Why?
|
| Health Status | 2 | 2017 | 408 | 0.130 |
Why?
|
| Adult | 8 | 2025 | 31622 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1161 | 0.130 |
Why?
|
| Prediabetic State | 1 | 2017 | 64 | 0.130 |
Why?
|
| Young Adult | 5 | 2024 | 9966 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2019 | 554 | 0.120 |
Why?
|
| Happiness | 1 | 2016 | 13 | 0.120 |
Why?
|
| Imidazoles | 1 | 2017 | 219 | 0.120 |
Why?
|
| Germinoma | 1 | 2016 | 32 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 64 | 0.120 |
Why?
|
| Indoles | 1 | 2017 | 201 | 0.120 |
Why?
|
| Arousal | 1 | 2016 | 81 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 211 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 221 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 384 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2017 | 284 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 486 | 0.110 |
Why?
|
| Mass Screening | 1 | 2021 | 831 | 0.110 |
Why?
|
| Cyclin B | 1 | 2014 | 23 | 0.110 |
Why?
|
| Oncogene Fusion | 1 | 2014 | 26 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3414 | 0.110 |
Why?
|
| Medulloblastoma | 1 | 2019 | 571 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1304 | 0.110 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 88 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 157 | 0.110 |
Why?
|
| Apolipoprotein E4 | 1 | 2014 | 47 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17394 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 148 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1883 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1304 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2018 | 373 | 0.110 |
Why?
|
| Prognosis | 3 | 2025 | 5017 | 0.110 |
Why?
|
| Environment | 1 | 2014 | 148 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2015 | 618 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 957 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 608 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 447 | 0.100 |
Why?
|
| Postural Balance | 1 | 2014 | 131 | 0.100 |
Why?
|
| Genomics | 2 | 2024 | 1652 | 0.100 |
Why?
|
| Emotions | 1 | 2016 | 367 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 127 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 856 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2017 | 937 | 0.100 |
Why?
|
| Mutation | 4 | 2023 | 6243 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2017 | 1121 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 486 | 0.100 |
Why?
|
| Speech | 2 | 2023 | 77 | 0.090 |
Why?
|
| Hearing Tests | 2 | 2023 | 16 | 0.090 |
Why?
|
| Sarcoma | 1 | 2014 | 207 | 0.090 |
Why?
|
| Incidence | 5 | 2019 | 3377 | 0.090 |
Why?
|
| Disease Management | 1 | 2016 | 565 | 0.090 |
Why?
|
| Diet | 1 | 2019 | 1125 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1234 | 0.090 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 54 | 0.090 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2023 | 80 | 0.090 |
Why?
|
| Germ Cells | 2 | 2024 | 204 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 613 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 4003 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2014 | 812 | 0.080 |
Why?
|
| Software | 1 | 2014 | 731 | 0.080 |
Why?
|
| Time Factors | 2 | 2019 | 6456 | 0.080 |
Why?
|
| Alleles | 1 | 2014 | 1684 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 1461 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8548 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2399 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1418 | 0.060 |
Why?
|
| Hospitalization | 1 | 2015 | 1902 | 0.060 |
Why?
|
| Audiometry | 2 | 2017 | 23 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2022 | 1402 | 0.060 |
Why?
|
| Tennessee | 2 | 2014 | 35 | 0.060 |
Why?
|
| Equivalence Trials as Topic | 1 | 2024 | 24 | 0.050 |
Why?
|
| Heart Failure | 1 | 2018 | 2398 | 0.050 |
Why?
|
| Hand Strength | 1 | 2024 | 61 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 89 | 0.050 |
Why?
|
| Social Networking | 1 | 2024 | 18 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1714 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 1980 | 0.050 |
Why?
|
| Smell | 1 | 2024 | 131 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 52 | 0.050 |
Why?
|
| Polysomnography | 1 | 2023 | 155 | 0.050 |
Why?
|
| Carotid Arteries | 1 | 2023 | 135 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2023 | 229 | 0.050 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 14 | 0.050 |
Why?
|
| Life Change Events | 1 | 2022 | 65 | 0.050 |
Why?
|
| Poisson Distribution | 1 | 2021 | 51 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 308 | 0.040 |
Why?
|
| Maryland | 1 | 2021 | 35 | 0.040 |
Why?
|
| Mississippi | 1 | 2021 | 36 | 0.040 |
Why?
|
| North Carolina | 1 | 2021 | 67 | 0.040 |
Why?
|
| Minnesota | 1 | 2021 | 180 | 0.040 |
Why?
|
| Social Class | 1 | 2022 | 207 | 0.040 |
Why?
|
| Bias | 1 | 2021 | 144 | 0.040 |
Why?
|
| Motor Activity | 1 | 2023 | 523 | 0.040 |
Why?
|
| Auditory Threshold | 1 | 2019 | 17 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 373 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2019 | 24 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 796 | 0.040 |
Why?
|
| Ethics Committees, Research | 1 | 2019 | 32 | 0.040 |
Why?
|
| China | 1 | 2020 | 290 | 0.040 |
Why?
|
| Exome | 1 | 2024 | 1087 | 0.040 |
Why?
|
| Ophthalmic Artery | 1 | 2019 | 23 | 0.040 |
Why?
|
| Mental Competency | 1 | 2019 | 53 | 0.040 |
Why?
|
| Ethics, Research | 1 | 2019 | 55 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 105 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 2019 | 58 | 0.040 |
Why?
|
| Longitudinal Ligaments | 1 | 2019 | 3 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 153 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2019 | 66 | 0.040 |
Why?
|
| Research Subjects | 1 | 2019 | 54 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1251 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 100 | 0.040 |
Why?
|
| Biomarkers | 2 | 2019 | 3402 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 430 | 0.040 |
Why?
|
| Disease Progression | 1 | 2025 | 2230 | 0.040 |
Why?
|
| Delirium | 1 | 2019 | 61 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 50 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 905 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 253 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2025 | 915 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 4538 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 946 | 0.030 |
Why?
|
| Contrast Media | 1 | 2021 | 507 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2017 | 53 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 343 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 156 | 0.030 |
Why?
|
| Research Design | 1 | 2021 | 743 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 409 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 734 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3632 | 0.030 |
Why?
|
| Internal-External Control | 1 | 2016 | 75 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 802 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 223 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 199 | 0.030 |
Why?
|
| Self Concept | 1 | 2016 | 164 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 461 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 425 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 277 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 998 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 604 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 988 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 59 | 0.030 |
Why?
|
| Minority Groups | 1 | 2016 | 250 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1612 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 761 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 403 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 348 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 455 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 724 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 576 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 1099 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2016 | 663 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 3139 | 0.020 |
Why?
|
| Patient Selection | 1 | 2016 | 732 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1575 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1842 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3737 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1901 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2314 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 3691 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2014 | 569 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1803 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 13034 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4690 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 34842 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 2087 | 0.010 |
Why?
|